Novartis Investigative Site

Badalona 08916

0 studies enrolling now · 8 studies all time

What they study most

Breast Cancer, Breast Neoplasms, Cancer, Carcinoma, Renal Cell, Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD), Heart Failure With Reduced Ejection Fraction (HF-rEF), Melanoma, Renal Cell Carcinoma (RCC)

Studies at this site

• Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). — Completed
• Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma — Completed
• Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer — Completed
• Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer — Completed
• Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF) — NO_LONGER_AVAILABLE
• A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) — Completed
• A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) — Completed
• A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo — Completed